Blog
RSS FeedPosted by Michael Wonder on 20 Jan 2020
Why cancelling your private health insurance could have unintended consequences
20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...
Posted by Michael Wonder on 17 Jan 2020
Pricing of pharmaceuticals is becoming a major challenge for health systems
13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...
Posted by Michael Wonder on 17 Jan 2020
Defining the concept of fair pricing for medicines
13 January 2020 - Suerie Moon and colleagues consider what makes a fair price for both buyers and sellers. ...
Posted by Michael Wonder on 16 Dec 2019
An evidence-based framework for identifying technologies of no or low-added value
13 December 2019 - This study's objective was to synthetise the state of the art of methods for identifying candidate technologies ...
Posted by Michael Wonder on 12 Dec 2019
Value-based pricing for gene therapy? Maybe not ready for haemophilia.
12 December 2019 - Insurers grappling with the million-dollar-plus costs of gene therapy have touted "value-based" arrangements that allow payment ...
Posted by Michael Wonder on 11 Dec 2019
Weighing costs and benefits in the economics of cancer care
10 December 2019 - Oncology is a profession and a calling to serve patients with cancer, but it is also an ...
Posted by Michael Wonder on 09 Dec 2019
Base drug prices on value rather than R&D
8 December 2019 - For decades, R&D spending on pharmaceuticals has gone up more or less in tandem with the ...
Posted by Michael Wonder on 26 Nov 2019
Using GRADE methodology to assess innovation of new medicinal products in Italy
25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...
Posted by Michael Wonder on 25 Nov 2019
ICER opens nominations for new members of its voting panels
25 November 2019 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 22 Nov 2019
The life improvement value: a new measure of cost-efficiency
23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 05 Nov 2019
Obscure model puts a price on good health—and drives down drug costs
4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...
Posted by Michael Wonder on 01 Nov 2019
Report clearly demonstrates the value of vaccines
1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...
Posted by Michael Wonder on 17 Oct 2019
Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines
17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...
Posted by Michael Wonder on 17 Oct 2019
Some say a non-profit research group unfairly influences drug prices
16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...